153 related articles for article (PubMed ID: 36557345)
1. Multiple Biomarker Simultaneous Detection in Serum via a Nanomaterial-Functionalized Biosensor for Ovarian Tumor/Cancer Diagnosis.
Wu Y; Wang C; Wang C; Wang P; Chang X; Han L; Zhang Y
Micromachines (Basel); 2022 Nov; 13(12):. PubMed ID: 36557345
[TBL] [Abstract][Full Text] [Related]
2. A high-performance microfluidic detection platform to conduct a novel multiple-biomarker panel for ovarian cancer screening.
Wu Y; Wang C; Wang P; Wang C; Zhang Y; Han L
RSC Adv; 2021 Feb; 11(14):8124-8133. PubMed ID: 35423342
[TBL] [Abstract][Full Text] [Related]
3. A Multiple-Array SPRi Biosensor as a Tool for Detection of Gynecological-Oncological Diseases.
Szymanska B; Lukaszewski Z; Hermanowicz-Szamatowicz K; Gorodkiewicz E
Biosensors (Basel); 2023 Feb; 13(2):. PubMed ID: 36832045
[TBL] [Abstract][Full Text] [Related]
4. An all-graphene quantum dot Förster resonance energy transfer (FRET) probe for ratiometric detection of HE4 ovarian cancer biomarker.
Bharathi G; Lin F; Liu L; Ohulchanskyy TY; Hu R; Qu J
Colloids Surf B Biointerfaces; 2021 Feb; 198():111458. PubMed ID: 33246782
[TBL] [Abstract][Full Text] [Related]
5. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
6. Detection of serum human epididymis secretory protein 4 in patients with ovarian cancer using a label-free biosensor based on localized surface plasmon resonance.
Yuan J; Duan R; Yang H; Luo X; Xi M
Int J Nanomedicine; 2012; 7():2921-8. PubMed ID: 22745553
[TBL] [Abstract][Full Text] [Related]
7. Correlation of Molecular Tumor Markers CA125, HE4, and CEA with the Development and Progression of Epithelial Ovarian Cancer.
Wan Q; Liu Y; Lv B; Chen X
Iran J Public Health; 2021 Jun; 50(6):1197-1205. PubMed ID: 34540740
[TBL] [Abstract][Full Text] [Related]
8. Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors.
Chen F; Shen J; Wang J; Cai P; Huang Y
Cancer Manag Res; 2018; 10():1313-1318. PubMed ID: 29861641
[TBL] [Abstract][Full Text] [Related]
9. Serum human epididymal protein 4 (HE4) as biomarker for the differentiation between epithelial ovarian cancer and ovarian metastases of gastrointestinal origin.
Stiekema A; Boldingh QJ; Korse CM; van der Noort V; Boot H; van Driel WJ; Kenter GG; Lok CA
Gynecol Oncol; 2015 Mar; 136(3):562-6. PubMed ID: 25560808
[TBL] [Abstract][Full Text] [Related]
10. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis.
Gąsiorowska E; Michalak M; Warchoł W; Lemańska A; Jasiński P; Spaczyński M; Nowak-Markwitz E
Ginekol Pol; 2015 Feb; 86(2):88-93. PubMed ID: 25807831
[TBL] [Abstract][Full Text] [Related]
11. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer.
Park Y; Kim Y; Lee EY; Lee JH; Kim HS
Int J Cancer; 2012 Mar; 130(5):1136-44. PubMed ID: 21484794
[TBL] [Abstract][Full Text] [Related]
12. Ultrasensitive, high-throughput and multiple cancer biomarkers simultaneous detection in serum based on graphene oxide quantum dots integrated microfluidic biosensing platform.
Wang C; Zhang Y; Tang W; Wang C; Han Y; Qiang L; Gao J; Liu H; Han L
Anal Chim Acta; 2021 Sep; 1178():338791. PubMed ID: 34482866
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.
Ren X; Zhang H; Cong H; Wang X; Ni H; Shen X; Ju S
Pathol Oncol Res; 2018 Oct; 24(4):739-744. PubMed ID: 29520570
[TBL] [Abstract][Full Text] [Related]
14. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
[TBL] [Abstract][Full Text] [Related]
15. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
[TBL] [Abstract][Full Text] [Related]
16. [Borderline Ovarian Tumours: CNGOF Guidelines for Clinical Practice - Value of Tumor Markers].
Nyangoh-Timoh K; Bendifallah S; Dion L; Ouldamer L; Levêque J
Gynecol Obstet Fertil Senol; 2020 Mar; 48(3):277-286. PubMed ID: 32004789
[TBL] [Abstract][Full Text] [Related]
17. Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?
Moore RG; Blackman A; Miller MC; Robison K; DiSilvestro PA; Eklund EE; Strongin R; Messerlian G
Gynecol Oncol; 2019 Jul; 154(1):150-155. PubMed ID: 30992143
[TBL] [Abstract][Full Text] [Related]
18. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
[TBL] [Abstract][Full Text] [Related]
19. HE4 as an Early Detection Biomarker of Epithelial Ovarian Cancer: Investigations in Prediagnostic Specimens From the Janus Serumbank.
Gislefoss RE; Langseth H; Bolstad N; Nustad K; Mørkrid L
Int J Gynecol Cancer; 2015 Nov; 25(9):1608-15. PubMed ID: 26501436
[TBL] [Abstract][Full Text] [Related]
20. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
